<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260373</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-106</org_study_id>
    <nct_id>NCT04260373</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.</brief_title>
  <official_title>A Phase I Mass Balance and Biotransformation Study of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]SHR4640 in
      Chinese healthy adult male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Actual">April 3, 2020</completion_date>
  <primary_completion_date type="Actual">April 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitive analysis of whole radioactivity of excrement of orally administered [14C]SHR4640 in Chinese healthy adult male volunteers to obtain the mass balance data and the main excretion pathway in human body by liquid scintillation counter.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled SHR4640 recovered in urine, faeces and in total, up to Day 10 (approx).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of the concentrations of SHR4640 in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>The concentrations of SHR4640 in plasma up to Day 10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the main metabolite and biotransformation pathway of SHR4640 and investigation of metabolite in plasma by LC-HR MS.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>Proportion of different metabolites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events.</measure>
    <time_frame>Up to 10 days (approx) from the start of administration.</time_frame>
    <description>Laboratory indicators, 12-lead electrocardiogram (ECG), physical examination,vital signs, adverse events (NCI-CTC AE 5.0), etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Adult Male Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]SHR4640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single dose of [14C]SHR4640 (Suspension, 10mg/80μCi).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]SHR4640</intervention_name>
    <description>Patients will receive single dose of orally [14C]SHR4640 on Day 1.</description>
    <arm_group_label>[14C]SHR4640</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signing the informed consent forms;

          2. Healthy adult males;

          3. Age: 18 Years to 45 Years(Including the boundary value);

          4. Weight: Body mass index(BMI) between 19 and 26 kg/m2(Including the boundary value);

        Exclusion Criteria:

          1. Persons with abnormal physical examination, routine laboratory examination (blood
             routine, urine routine, stool routine + occult blood, blood biochemistry, blood
             coagulation routine, thyroid function), complete set of sex hormones, 12-lead
             electrocardiogram, X-ray (orthotopic), abdominal b-ultrasound (liver, bile, pancreas,
             spleen and kidney) and clinical significance;

          2. Hepatitis b surface antigen, e antigen, hepatitis c antibody, HIV antibody and
             syphilis antibody, any one of these is positive.

          3. Any medication taken within 14 days prior to screening;

          4. Taking any clinical trial drug or participating in any clinical trial of any drug
             within 3 months prior to the screening period or preparing to participate in any other
             clinical trial within 1 month after the end of this trial;

          5. Persons with history of organic heart disease, heart failure, myocardial infarction,
             angina pectoris, cardiac arrhythmias can not be explained, reverse sexual ventricular
             tachycardia, ventricular tachycardia, lengthened QT syndrome history or have QT
             syndrome symptoms and family history;

          6. Persons who underwent major surgery within 6 months before the screening period or the
             surgical incision was not completely healed;Major surgery includes, but is not limited
             to, any operation with significant risk of bleeding, prolonged general anesthesia,
             open biopsy or significant traumatic injury;

          7. A history of any clinical serious illness or disease or condition that the
             investigator believes may affect the results of the study, including but not limited
             to a history of circulatory, endocrine, nervous, digestive, urinary or blood, immune,
             mental and metabolic diseases;

          8. Subject with known hypersensitivity or allergy to SHR4640, or any component of
             SHR4640;

          9. Hemorrhoids or perianal disease with regular/ongoing hematochezia;

         10. Subjects who have habitual constipation or diarrhea, irritable bowel syndrome,
             inflammatory bowel disease;

         11. Those who have history of alcohol abuse 1 month prior to screening period, or the
             alcohol breath test results ≥20 mg/dl during screening period；

         12. Subjects who smoked daily &gt;5 sticks of cigarette 3 months prior to first dose or
             cannot give up smoking during study;

         13. Subjects who have history of drug abuse or taking soft drug (i.e., marihuana) 3 months
             prior to screening period or taking hard drugs (i.e., cocaine, amphetamines,
             benzodiazepine, etc.); or the results of urine test in drugs were positive;

         14. Subjects who were used to drink grapefruit juice or overconsumption of tea, coffee,
             and the drink with caffeine; and cannot give up them during test;

         15. Subjects who need long-term exposure to radiation, or who have been exposed to PET-CT
             or ECT within 3 months prior to study drug administration or who have participated in
             the labeling test of radiopharmaceuticals;

         16. Subjects who have fertility planning within the range of starting trial - 1 year after
             finishing trial;

         17. Subjects who have excessive bleeding or blood donation (400ml) 3 months prior to
             screening period, or planned to donate blood 1 month after finishing this trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Affiliated Hospital, Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

